1-17 of 17
Amer M. Zeidan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1 -mutant AML

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Rebecca P. Bystrom, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos Perez, Anthony Stein, Vinod Pullarkat, Ibrahim Aldoss, Daniel J. DeAngelo, Donna S. Neuberg, Richard M. Stone, Sylvain Garciaz, Brian Ball, Maximilian Stahl
Journal: Blood Advances
Blood Adv (2024) 8 (18): 4845–4855.
https://doi.org/10.1182/bloodadvances.2024012858
Published: 2024
Includes: Supplemental data
Journal Articles

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials

Clinical Trials & Observations
Pau Montesinos, Amir T. Fathi, Stéphane de Botton, Eytan M. Stein, Amer M. Zeidan, Yue Zhu, Thomas Prebet, Carlos E. Vigil, Iryna Bluemmert, Xin Yu, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2509–2519.
https://doi.org/10.1182/bloodadvances.2023011914
Published: 2024
Includes: Supplemental data
Journal Articles

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence

Rory M. Shallis, Rong Wang, Amer M. Zeidan, Scott F. Huntington, Natalia Neparidze, Jessica M. Stempel, Lourdes M. Mendez, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3213–3224.
https://doi.org/10.1182/bloodadvances.2022009074
Published: 2023
Journal Articles

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Clinical Trials & Observations
Maximilian Stahl, Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F. Sanz, David A. Sallman, Valeria Santini, Gail J. Roboz, Mrinal M. Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D. Nimer, Ravindra Majeti, Richard F. Little, Steven Gore, Alan F. List, Vijay Kutchroo, Rami S. Komrokji, Tae Kon Kim, Nina Kim, Christopher S. Hourigan, Robert P. Hasserjian, Stephanie Halene, Elizabeth A. Griffiths, Peter L. Greenberg, Maria Figueroa, Pierre Fenaux, Fabio Efficace, Amy E. DeZern, Matteo G. Della Porta, Naval G. Daver, Jane E. Churpek, Hetty E. Carraway, Andrew M. Brunner, Uma Borate, John M. Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P. Steensma, Mikkael A. Sekeres, Rena J. Buckstein, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2709–2714.
https://doi.org/10.1182/bloodadvances.2022008747
Published: 2023
Journal Articles

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea

Rong Wang, Rory M. Shallis, Jessica M. Stempel, Scott F. Huntington, Amer M. Zeidan, Steven D. Gore, Xiaomei Ma, Nikolai A. Podoltsev
Journal: Blood Advances
Blood Adv (2023) 7 (5): 734–743.
https://doi.org/10.1182/bloodadvances.2022008259
Published: 2023
Journal Articles

Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis

Mengyang Di, Can Cui, Shalin K. Kothari, Amer M. Zeidan, Nikolai A. Podoltsev, Natalia Neparidze, Rory M. Shallis, Rong Wang, Xiaomei Ma, Scott F. Huntington
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3339–3342.
https://doi.org/10.1182/bloodadvances.2021006934
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Andrzej Hellmann, David C. Taussig, Mar Tormo, Maria Teresa Voso, James Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2219–2229.
https://doi.org/10.1182/bloodadvances.2021006138
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Ken Ogasawara, James Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2207–2218.
https://doi.org/10.1182/bloodadvances.2021005487
Published: 2022
Includes: Supplemental data
Journal Articles

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States

Clinical Trials & Observations
Jan Philipp Bewersdorf, Stephanie Prozora, Nikolai A. Podoltsev, Rory M. Shallis, Scott F. Huntington, Natalia Neparidze, Rong Wang, Amer M. Zeidan, Amy J. Davidoff
Journal: Blood Advances
Blood Adv (2022) 6 (2): 376–385.
https://doi.org/10.1182/bloodadvances.2021005642
Published: 2022
Includes: Supplemental data
Journal Articles

Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia

Clinical Trials & Observations
Jan Philipp Bewersdorf, Kishan K. Patel, Scott F. Huntington, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4686–4690.
https://doi.org/10.1182/bloodadvances.2021005472
Published: 2021
Includes: Supplemental data
Journal Articles

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia

Kishan K. Patel, Amer M. Zeidan, Rory M. Shallis, Thomas Prebet, Nikolai Podoltsev, Scott F. Huntington
Journal: Blood Advances
Blood Adv (2021) 5 (4): 994–1002.
https://doi.org/10.1182/bloodadvances.2020003902
Published: 2021
Includes: Supplemental data
Journal Articles

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents

Clinical Trials & Observations
Smith Giri, Scott F. Huntington, Rong Wang, Amer M. Zeidan, Nikolai Podoltsev, Steven D. Gore, Xiaomei Ma, Cary P. Gross, Amy J. Davidoff, Natalia Neparidze
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2245–2253.
https://doi.org/10.1182/bloodadvances.2019001425
Published: 2020
Journal Articles

Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States

Clinical Trials & Observations
Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Rory M. Shallis, Nikolai A. Podoltsev, Jan P. Bewersdorf, Scott F. Huntington, Natalia Neparidze, Smith Giri, Steven D. Gore, Amy J. Davidoff, Xiaomei Ma
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2192–2201.
https://doi.org/10.1182/bloodadvances.2020001779
Published: 2020
Includes: Supplemental data
Journal Articles

Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States

Amer M. Zeidan, Nikolai A. Podoltsev, Xiaoyi Wang, Chi Zhang, Jan Philipp Bewersdorf, Rory M. Shallis, Scott F. Huntington, Natalia Neparidze, Smith Giri, Steven D. Gore, Amy J. Davidoff, Xiaomei Ma, Rong Wang
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1615–1623.
https://doi.org/10.1182/bloodadvances.2020001728
Published: 2020
Journal Articles

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera

Clinical Trials & Observations
Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore, Xiaomei Ma
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2681–2690.
https://doi.org/10.1182/bloodadvances.2018021436
Published: 2018
Includes: Supplemental data
Journal Articles

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres, Andrew M. Brunner, Gail J. Roboz, David P. Steensma, Vijaya R. Bhatt, Uwe Platzbecker, Thomas Cluzeau, Pedro H. Prata, Raphaël Itzykson, Pierre Fenaux, Amir T. Fathi, Alexandra Smith, Ulrich Germing, Ellen K. Ritchie, Vivek Verma, Aziz Nazha, Jaroslaw P. Maciejewski, Nikolai A. Podoltsev, Thomas Prebet, Valeria Santini, Steven D. Gore, Rami S. Komrokji, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1765–1772.
https://doi.org/10.1182/bloodadvances.2018019414
Published: 2018
Journal Articles

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John D. Barnard, Nikolai A. Podoltsev, Andrew M. Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T. Fathi, Gail J. Roboz, Pierre Fenaux, Mark R. Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (8): 923–932.
https://doi.org/10.1182/bloodadvances.2018016121
Published: 2018
Includes: Supplemental data